Amgen Hits Another Emerging Market Target With $700M Turkish Deal
This article was originally published in The Pink Sheet Daily
Fulfilling its pledge to dramatically expand internationally, Amgen sealed a deal to purchase coveted drugmaker Mustafa Nevzat, gaining a foothold in Turkey. Meanwhile, its pipeline progresses with no clear winners to help cushion the blows to the company’s ESAs.
You may also be interested in...
Amgen Shrugs Off Turkish Price Cuts, Snatches Up Mustafa Nevzat For Broader Reach Into Emerging Markets
Despite harsh price cuts in Turkey that have taken a toll on multinationals, Amgen dives head first into the market.
Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.
PCSK9 inhibitors have come into vogue based on potent LDL-lowering in early studies. But the up-and-coming biologics still face questions about how they will fit in a market dominated largely by proven, oral generics.